|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Changes in thelevels of serotonin and dopamine in the central nervous systemand ovary, and their possible roles in the ovarian development inthe giant freshwater prawn, Macrobrachium rosenbergii 显示文摘 | Tinikul Y Joffre Mercier A Soonklang N | 2008 | GenComp Endocrinol2008，158，3： | 1 |
| 2 | Bilateral eyestalk ablation of the blue swimmer crab, Portunus pelagicus , produces hypertrophy of the androgenic gland and an increase of cells producing insulin-like androgenic gland hormone显示文摘 | Morakot Sroyraya Charoonroj Chotwiwatthanakun Michael J. Stewart Nantawan Soonklang Napamanee Kornthong Ittipon Phoungpetchara Peter J. Hanna Prasert Sobhon | 2010 | Tissue and Cell2010，，5： | 1 |
| 3 | Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area显示文摘AIM To determine the role of screening and surveillance of hepatocellular carcinoma(HCC) in treatment-na?ve chronic hepatitis B(CHB) patients. METHODS We recruited 2293 CHB patients(both males and females; aged 20-65 years). All patients were screened and underwent surveillance using abdominal ultrasonography(AUS) and serum alpha-fetoprotein(AFP) assay every 6 mo. The diagnosis,staging and treatment of HCC followed the American Association for the Study of Liver Diseases practice guidelines and the Barcelona Clinic Liver Cancer guidelines. The exclusion criteria included: decompensated cirrhosis; a history of any cancer in the last 5 years; previous antiviral treatment for CHB; concurrent infection with hepatitis C virus or human immunodeficiency virus; a Karnofsky Performance Status score < 60%; or any medical condition preventing eligibility to complete the protocol. The prevalence and incidence rates of HCC were determined; survival rates were calculated at 3-year post HCC diagnosis. The sensitivity and specificity were calculated on a per-patient basis.RESULTS Among 2293 treatment-na?ve CHB patients,seven cases had HCC at initial screening,giving a prevalence rate of 305 per 100000 persons; 3.3% were diagnosed with liver cirrhosis,all of which were Child-Pugh class A. With a median follow-up time of 42(range,3-48) mo,10 additional cases were diagnosed with HCC,resulting in an incidence rate of 143 per 100000 persons per year. This burden was as high as that reported in other studies from East Asian countries. All HCC patients were aged ≥ 40 years. Most were at an early stage(Stage 0,A or B); 14/17 cases were successfully treated with surgical resection or radiofrequency ablation,with a high 3-year survival rate of 90%. Hemangioma was the most common focal liver lesion in CHB patients detected by AUS; the main causes of AFP elevation at the initial screening were cirrhosis,increased alanine aminotransferase level and HCC. AUS detected 16/17 HCC cases whereas AFP levels ≥ 20 mg/L at diagnosis were observed in only 7/17 patients,most with a tumor size > 5 cm. For HCC screening and surveillance,AUS had a sensitivity and specificity of 94% and 82%,respectively,whereas the sensitivity and specificity of AFP at a cut-off value of ≥ 20 mg/L were 41% and 98%,respectively. Combined use of AUS and AFP assay did not improve effectiveness. CONCLUSION Implementation of active screening and surveillance using AUS to detect early-stage HCC in na?ve CHB patients aged ≥ 40 years in an endemic area is of benefit. | Teerapat Ungtrakul Chulabhorn Mahidol Pattra Chun-on Charlie Laohapand Surachate Siripongsakun Akeanong Worakitsitisatorn Sirachat Vidhayakorn Wariya Boonchuay Jiraporn Dechma Gaidganok Sornsamdang Kamonwan Soonklang Tassanee Sriprayoon Tawesak Tanwandee Chirayu U Auewarakul | 2016 | World Journal of Gastroenterology2016，22，34： | 1 |
| 4 | Protection of inactivated vaccine against SARS-CoV-2 infections in patients with comorbidities:a prospective cohort study显示文摘Protection against severe acute respiratory syndrome Coronavirus 2(SARS-CoV-2)infection of inactivated vaccines is not well characterized in people with comorbidities,who are at high risk of severe infection.We compared the risk of SARS-CoV-2 infection after complete vaccination with Sinopharm/BBIBP in people with comorbidities(e.g.,autoimmune diseases,cardiovascular disease,chronic lung disease,and diabetes)with healthy individuals using a Cox-proportional hazard model.In July-September 2021,a total of 10548 people(comorbidities,2143;healthy,8405)receiving the complete primary series of vaccination with Sinopharm/BBIBP in Bangkok,Thailand were prospectively followed for SARS-CoV-2 infection through text messaging and telephone interviewing for 6 months.A total of 295 infections from 284 participants were found.HRs(95%CI)of individuals with any comorbidities did not increase(unadjusted,1.02(0.77–1.36),P=0.89;adjusted,1.04(0.78–1.38),P=0.81).HRs significantly increased in the subgroup of autoimmune diseases(unadjusted,2.64(1.09–6.38),P=0.032;adjusted,4.45(1.83–10.83),P=0.001)but not in cardiovascular disease,chronic lung disease,or diabetes.The protection against SARS-CoV-2 infection of the Sinopharm vaccine was similar in participants with any comorbidities vs.healthy individuals.However,the protection appeared lower in the subgroup of autoimmune diseases,which may reflect suboptimal immune responses among these people. | Kanchana Ngaosuwan Kamonwan Soonklang Chawin Warakul Chirayu Auewarakul Nithi Mahanonda | 2023 | Frontiers of Medicine2023，17，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员